The Food and Drug Administration (FDA) has approved Ibsrela (tenapanor; Ardelyx) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Eluxadoline appears to be a safe and effective treatment for the symptoms of irritable bowel syndrome with diarrhea (IBS-D) in patients with intact gallbladders who have previously reported inadequate relief with loperamide.
Further studies will need to look at different subtypes of IBS (IBS-diarrhea, IBS-constipation, IBS-mixed) and improved breath testing, as well as evaluating underlying gut microbiome profiles and how they may affect a response to a low FODMAP diet.
Low vitamin D levels have been linked to multiple diseases including some cancers, neurologic disorders, decrease in bone density, and cognitive decline in the elderly, and research suggests that a possible inflammatory response in the gut when vitamin D levels are low may cause irritable bowel syndrome.
Compared with computed tomographic (CT) scan, point-of-care ultrasonography has demonstrated high accuracy in diagnosing small bowel obstruction in the emergency department, which may result in a significantly shorter time to diagnosis.
Recommendations aim to help clinicians in choosing appropriate laboratory tests to exclude other diagnoses in the setting of suspected functional diarrhea or diarrhea-predominant irritable bowel syndrome.